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SUMMARY : An immunohistochemical study of EGF, and products of ras and 
myc oncogenes was carried out in 47 cases of non-neoplastic and neoplastic lesions 
of the thyroid. Normal thyroid tissues showed no significant immunostaining 
reaction to antibodies for EGF, and products of ras and myc oncogenes. The 
incidence of EGF positivity was 27%, 46% and 76% in Graves' disease, follicular 
adenoma, and carcinoma, repectively. The incidence of positivity of ras oncogene 
product was 27%, 38%, and 82% in Graves' disease, follicular adenoma and car-
cinoma, respectively. The incidence of positivity of myc oncogene product was 18%, 
46% and 71% in Graves' disease, Follicular adenoma, and carcinoma, respectively. 
These results suggest that EGF, and ras and myc oncogenes or proto-oncogenes play 
a role in neoplastic lesions of the thyroid.
       INTRODUCTION 
 Oncogenes are nucleotides present in the 
genome of neoplastic cells, and they have been 
known to be differentiated from protoonco-
genes which are supposed to be important for 
normal cellular growth and differentiation (3). 
Recent investigations have suggested that 
various cellular oncogenes are expressed in 
human cancer tissues (17). To date about 40 
oncogenes have been isolated and characterized. 
With regard to transformation of protoonco-
gene to oncogene, three major types of 
processes have been postulated as follows : 1) 
amplification of oncogenes, 2) rearrangement 
of oncogenes and 3) point-mutations (23). The 
hypothesis has been proposed that at least two
kinds of oncogenes such as myc and ras are 
required in carcinogenesis (11). We have 
previously reported that ras and myc oncogene 
products are expressed in human coronary 
atherosclerotic lesions which are pathologi-
cally categorized as degenerative and non-
neoplastic disease (21).. These results prompted 
us to reevaluate the expression of several 
oncogenes in pathological lesions in various 
tissues because results are conflicting. This 
report describes an immunohistochemical 
identification of EGF, and products of ras and 
myc oncogenes in non-malignant and malig-
nant thyroid tissues.
  MATERIALS AND METHODS 
We examined six autopsy cases with normal
thyroid and a total of forty-one sugical cases 
including 11 Graves' disease, 13 adenoma and 
17 carcinoma. Diagnosis was maid according 
to WHO histological classification of thyroid 
tumors (6). Affinity purified monoclonal anti-
bodies for EGF, ras and myc oncogene products 
(Oncor ) were used in this study. Indirect 
immunoperoxidase (PAP) staining (18) was 
performed on 4 micrometer thick sections of 
formalin-fixed, paraffin-embedded tissues. 
Secondary antibody (rabbit antisheep immuno-
globulin) and sheep PAP were purchased from 
Dakopatts. The sections were stained with 3', 
3-diaminobenzidine hydrochloride solution and 
countersatined with hematoxylin. Omission of 
the primary antibodies and substitution of the 
primary antibodies with non-immune sera were 
used as negative control. The degree of 
immunoreactivity was expressed as the follow-
ing : + +, definitely positive +, weakly 
positive ; -, negative. 
          RESULTS 
 Table 1 shows the results of immunohisto-
chemical staining of EGF in various types of 
thyroid tissues. Thyroid tissues examined 
included a total of fourty seven cases including 
6 normal thyroids, 11 Graves' disese, 13 folli-
cular adenoma, 15 papillary carcinoma, and 2 
follicular carcinoma. Normal thyroid tissues 
were collected from the middle-aged autopsy 
cases. These thyroid tissues showed various 
sizes of follicles which were composed of flat 
follicular epithelium and moderately dense 
eosinophilic colloid material. Immunostaining 
of EGF gave no reaction of EGF antibody to 
normal thyroid tissues (Fig. 1 ). Histological
Fig. 1. No . EGF is demonstrated in flat folli-
      cular epithelial cells of the normal thy-
      roid (PAP stain X 150). 
findings of the thyroid tissues with Graves' 
disease were variable because all the cases were 
placed on medication for certain duration 
before surgical operation. Most of the folli-
cular epithelium of the thyroid with Graves' 
disease were cuboidal. Colloid material was 
weakly stained with eosin. Small vacuoles were 
occasionally seen along the luminal surface of 
the follicular epithelium. EGF was slightly to 
moderately demonstrated in hyperplastic foci 
of cuboidal epithelium which were seen in three 
of the 11 cases of Graves' diseases (Fig.2). The 
thyroid tissues which were negative for EGF 
antibodies consisted of various size of follicles 
having flat epithelium. The follicular adenoma 
had a well defined capsule and was composed 
of various sizes of follicles showing a trabe-
cular or tubular pattern. In this study, histo-
logical subtypes of follicular adenoma was not 
used because the number of follicular adenoma 
cases was not sufficient. Six of thirteen 
follicular adenoma cases showed definitely or
  Table 1. Immunoreactivity for EGF in various types 
          of thyroid tissues. 
                                  Immunoreactivity 
 Diagnosis Number of cases 
                           ++ + -
Normal 6 0/ 6 0/ 6 6/ 6 
Graves' disease 11 1/11 2/11 8/11 
Follicular adenoma 13 2/13 4/13 7/13 
Carcinoma papillary 15 8/15 3/15 4/15           f
ollicular 2 1/ 2 1/ 2 0/ 2 
+ + : definitely positive, + : weakly positive, - : negative
tissues (Fig. 5 & 6).
Fig. 2. Hyperplastic cuboidal follicular epithe-
       lial cells are weakly positive for EGF 
      antibodies (PAP stain X 150).
Fig. 3. Definitely EGF positive cells (P ) are 
       focally seen in adenoma (PAP stain X
     150).
Fig. 4. Note definitely positive reaction of EGF 
      antibody in papillary (A) and follicular 
      (B) carcinomas (PAP stain X150).
weakly positive reaction (Fig. 3 ). Epithelial 
cells of papillary carcinoma were characterized 
by the presence of pale ground-glass nuclei and 
clear or oxyphilic cytoplasm. Calcified spheri-
cles were occasionally seen in papillary carci-
noma. Depending upon the degree of differen-
tiation, follicular carcinoma showed follicular 
and trabecular patterns and solid masses of 
tumor cells. Tumor cells of follicular carcinoma 
possessed the hyperchromatic nuclei and the 
similar cytoplasm to those of the normal 
follicular cells. Positive reaction of EGF was 
seen in 76% of carcinomas including 11 papi-
llary and two follicular carcinomas (Fig. 4). 
Immunohistochemical staining pattern of the 
products of ras and myc oncogenes were similar 
to that of EGF in various types of thyroid
Fig. 5. Papillary carcinoma showing definitely 
      positive staining of antibody for myc 
      oncogene product (PAP stain X150). 
 Table 2 and 3 present the incidence of immuno-
histochemical positivity of products of ras and 
myc oncogenes, respectively. Products of ras
Fig. 6. Follicular carcinoma showing definite-
       ly positive staining of antibody for ras 
      oncogene product (PAP stain X 150). 
and myc oncogenes were more frequently and 
intensely demonstrated in carcinoma cases 
than in the adenoma cases and Graves' disease. 
        DISCUSSION 
 Radioimmunoassay studies reported that 
EGF is a physiologically occuring plasma 
hormone and is contained in a relatively higher 
amount in human thyroid tissues than in other 
tissues (7, 8). Kesselberg et al. (10) investigat-
ed immunocytochemical localization of human 
epidermal growth factor in several human 
tissues and they found no significant EGF in 
the normal thyroid tissue. The cause of this 
discrepancy is unknown. However, the present 
immunohistochemical study demonstrated no 
significant amount of EGF in normal thyroid 
tissues. Recent study indicated that c-erbB is a 
truncated form of the EGF-R gene and the 
content of EGF in the thyroid tissue is regulat-
ed by the EGF-recepter (4). Therefore, much 
attention have been paid to the relationship 
between EGF and various tumors such as 
thyroid carcinoma (12). Duh et al. (5) reported 
that the binding of EGF to thyroid neoplasm 
is higher than the normal thyroid tissue. It has 
been reported that both EGF and EGF-recepter 
are highly expressed in esophageal cancer (19). 
The present immunohistochemical study 
suggests that thyroid tissue of carcinoma 
contains more abundant EGF than that of the 
other non-neoplastic lesioins. We found that 
normal arterial tissue contains more EGF than 
the arteial tissue with atherosclerotic lesions 
(unpublished data ). Therefore, we have an 
impression that oncogenes are differently 
expressed depending upon types of tissues and
 Table 2. Immunoreactivity for ras oncogene product 
          in various types of thyroid tissues 
                                  Immunoreactivity 
Diagnosis Number f cases 
                           ++ + -
Normal 6 0/ 6 0/ 6 6/ 6 
Graves' disease 11 0/11 3/11 8/11 
Follicular adenoma 13 1/13 4/13 8/13 
Carcinoma papallary 15 7/15 5/15 3/15           f
ollicular 2 2/ 2 0/ 2 0/ 2 
+ + : definitely positive, + : weakly positive, - : negative 
 Table 3. Immunoreactivity for myc oncogene product 
          in various types of thyroid tissues 
                                  Immunoreactivity 
Diagnosis Number f cases 
                          ++ + -
Normal 6 0/ 6 1/ 6 5/ 6 
Graves' disease 11 0/11 2/11 9/11 
Follicular adenoma 13 3/13 3/13 7/13 
Carcinoma papallary 15 6/15 4/15 5/15          f
ollicular 2 1/ 2 1/ 2 0/ 2 
+ + : definitely positive, + : weakly positive, - : negative
maturity of non-tumor and tumors. 
 It has been reported that members of the 
ras family of cellular oncogenes are most 
frequently detected in human solid tumors (14, 
15). The result of present immunohistochemical 
study was consistent with the report by 
Yoshida et al. (25) that thyroid adenocarcinoma 
and adenoma express significantly more ras 
oncogene product than were seen in non-
neoplastic diseases such as Graves' disease. 
Contrary to these results, Johnson et al. (9) 
reported that ras oncogene p 2l antigen is 
expressed in inflammatory and non-neoplastic 
proliferative thyroid lesions as well as in 
benign and maliganat thyroid tumors. They 
have also pointed out that monoclonal antibody 
reacts both with the pointmutated and proto-
oncogene, and that it is unclear whether the 
increased products of oncogene in various 
thyroid lesions reflects point-mutaion of the 
ras gene or enhanced expression of ras proto-
oncogene. 
 The cellular myc oncogene is also one of the 
well known oncogenes which are expressed in 
human cancer tissues (1, 2, 16 ). Yamashita et 
al. (24) reported that normal thyroid tissues 
did not contain myc RNA sequences but that 
benign thyroid follicular adenoma and papilarry 
thyroid cancer tissues possessed myc RNA 
sequences. On the other hand, Terrier et al. (20) 
reported that it is not clear that the frequent 
expression of c-myc in the most malignant 
thyroid cancer is the cause or the consequence 
of this malignancy. In the present study, both 
ras and myc oncogene products were more 
abundantly demonstrated in neoplastic thyroid 
tissues than in non-neoplastic thyroid tissues. 
These two oncogene products were also demons-
trated in the transitional phase from fibro-
cellular intimal thickening lesions to 
atherosclerotic lesions of human coronay 
arteries (21), although the intensity of their 
reaction was weaker than that of the neolastic 
thyroid tissue. Furthermore, we demonstrated 
myc oncogene product in the aortic tissues of 
the chick embryo and atherosclerotic lesion of 
the chicken aorta (22). Pfeiffer-Ohlsson et al. 
(13) speculated that the myc gene activity is 
not simply a marker of proliferative activity 
but reflects additional tissue specific gene regu-
lation operating during human embryogen esis. 
 Finally, the present data suggest that EGF, 
and ras and myc oncogenes play a role in 
thyroid neoplasia. Further study using mole-
cular biological technique has been under way 
in our laboratory to examine whether the 
oncogene expression is qualitatively different 
in types of tissues and lesions or there exist 
complex interaction of oncogenes or some other 
factors are . involved in carcinogenesis. 
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